Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Signalling Pathways 2014

ESMO gratefully acknowledges the valuable contribution of the following organisations in the ESMO Symposium on Signalling Pathways 2014 – Targeting the PI3K/AKT/mTOR Pathway in Cancer.

Premium Educational Grants

Novartis Oncology

One Health Plaza
East Hanover, NJ 07936-1080
United States of America
Tel: +1 888 669 6682
Web: www.novartisoncology.com

Novartis Oncology discovers and develops innovative therapies, including Glivec® (imatinib), Tasigna® (nilotinib), Jakavi®(ruxolitinib), Afinitor® (everolimus), Zometa® (zoledronic acid), Femara® (letrozole), Sandostatin® LAR® (octreotide acetate for injectable suspension), Signifor®(pasireotide) and Exjade® (deferasirox). Novartis has one of the broadest and most comprehensive oncology pipelines in the industry.

F.Hoffmann-La Roche

Grenzacherstrasse 124
4070, Basel
Switzerland
Tel: +41 61 688 11 11
Fax: +41 61 691 93 91
Web: www.roche.com

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, and a leader in oncology. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings